SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
DISCLOSURES
As of 20 May 2020, 97 patients with RRMM received cilta-cel (phase 1b: 29; phase 2: 68). Median
follow-up was 8.8 months (1.5–20.4). Median prior lines of therapy (LoT) was 6 (3–18), 83.5% were
penta-exposed, 87.6% triple-refractory, 41.2% penta-refractory, and 97.9% refractory to last LoT.
Overall response rate per independent review committee was 94.8% (95% CI 88.4–98.3); 55.7%
stringent complete responses, 32.0% very good partial responses, and 7.2% partial responses. M-protein
was reduced in all patients. Median time to first response was 1.0 month (0.9–5.8; 80.4% ≤1.0
month), and median time to ≥complete response was 1.8 months (0.9–12.5; 74.1% ≤3.0 months) with
deepening of responses over time (Figure). Of 52 MRD-evaluable patients, 94.2% were MRD-negative
at 10-5. The 6-month progression-free survival (PFS) and overall survival (OS) rates (95% CI) were 87.4%
(78.9–92.7) and 93.8% (86.7–97.2), respectively. Median duration of response, PFS, and OS were not
reached. Ten deaths were reported: 6 due to related and 2 to unrelated AEs (CRS/hemophagocytic
lymphohistiocytosis, neurotoxicity, respiratory failure, sepsis, septic shock, pneumonia, lung abscess,
and acute myelogenous leukemia n=1 each), and 2 from progressive disease. AEs included CRS
(94.8%; grade 3/4 4.1%), neutropenia (90.7%; grade 3/4 90.7%), anemia (81.4%; grade 3/4 68.0%), and
thrombocytopenia (79.4%; grade 3/4 59.8%). Median time to CRS onset was 7.0 days (1–12) and
median duration 4.0 days (1–27, excluding n=1 with 97 days). 20.6% of patients had CAR-T cell–related
neurotoxicity (grade 3/4 10.3%). CAR+ T cells showed peak peripheral expansion at 14 days (9–43).
Among patients with 6-month follow-up, 67% had cilta-cel CAR+ T cells below the level of
quantification (2 cells/μL) in peripheral blood.
Preliminary results of CARTITUDE-1 indicate a single low-dose infusion of cilta-cel leads to early, deep,
and durable responses in heavily-pretreated patients with RRMM with safety consistent with LEGEND-
2.